Dr. David L. Bartlett, MD
Surgical Oncology (Surgical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 28
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Surgical Oncology Physician primary
PA license MD044852E -
Surgery Physician
PA license MD044852E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- West Penn Hospital Pittsburgh, PA
Medical groups
- Allegheny Clinic (2,389 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 28
- Services billed
- 72
- Patients’ average age
- 72
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $60,600 in research payments for these studies, mostly to the institutions running them.
- Fast TILs to Treat Metastatic Cancer Patients with Pleural Disease: A Phase I Trial
Iovance Biotherapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.